Clinical trials: Pharmacokinetics of ASP3652
Pharmacokinetics of ASP3652, Pharmacodynamics of ASP3652
A Study to Investigate the Appearance and Disappearance of ASP3652 in Blood and Spinal Fluid in Healthy Male Subjects
The purpose of this study is to evaluate the plasma and cerebrospinal fluid (CSF) pharmacokinetics (PK) of multiple doses of ASP3652 in healthy young Caucasian male subjects.
- Conditions
- Pharmacokinetics of ASP3652, Pharmacodynamics of ASP3652, Healthy Subjects
- Trial name
- NCT02034734
- Testing
- ASP3652
- Where
- United Kingdom
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
Healthy Subjects, Pharmacokinetics of ASP3652
A Study to Assess the Safety, Tolerability, and Effects in and on the Body of Healthy Young and Elderly Male and Female Subjects of Ascending Multiple Oral Doses of ASP3652
The study investigates how safe ASP3652 is and how well it is tolerated when taken as multiple doses. The study also assesses how quickly and to what extent it is absorbed and eliminated from the body.
- Conditions
- Healthy Subjects, Pharmacokinetics of ASP3652, Pharmacodynamics of ASP3652
- Trial name
- NCT02243657
- Testing
- ASP3652
- Where
- Netherlands
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
Cystitis, Interstitial, Urinary Bladder Disease
A Randomized Study Comparing Placebo and ASP3652 in the Treatment of Women With Bladder Pain Syndrome / Interstitial Cystitis (BPS/IC)
In this study several dose levels of ASP3652, given orally for 12 weeks, will be compared with placebo in the treatment of female patients with Bladder Pain Syndrome / Interstitial Cystitis.
- Conditions
- Cystitis, Interstitial, Urinary Bladder Disease, Pain, Urologic Diseases
- Trial name
- AMARANTH (NCT01613586)
- Testing
- ASP3652
- Where
- 60 sites in Belgium, Czechia and 10 more
- Volunteers
- 287 people
- Sponsor
- Astellas Pharma Europe B.V.
Chronic Abacterial Prostatitis, Chronic Pelvic Pain Syndrome
A Clinical Study to Investigate the Efficacy, Safety and Pharmacokinetics of ASP3652 in Patients With Chronic Abacterial Prostatitis / Chronic Pelvic Pain Syndrome (CP/CPPS)
In this study several doses of ASP3652, given orally for 12 weeks, will be compared with placebo in the treatment of patients with Chronic abacterial Prostatitis / Chronic Pelvic Pain Syndrome.
- Trial name
- AZURE (NCT01391338)
- Testing
- ASP3652
- Where
- 49 sites in Czechia, Germany and 4 more
- Volunteers
- 239 people
- Sponsor
- Astellas Pharma Inc
Pharmacokinetics, Pharmacodynamics
A Study to Assess the Safety, Tolerability and Effects of Single Ascending Doses of ASP3652 in Healthy Subjects
The purpose of this study is to explore the safety (including the effect on cardiac intervals), tolerability, the effects on the Central Nervous System (CNS), as well as the CNS side effect profile of single ascending doses of…
- Conditions
- Pharmacokinetics, Pharmacodynamics, Healthy Subjects, Safety
- Trial name
- NCT01815684
- Testing
- ASP3652
- Where
- Netherlands
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
Healthy Subjects, Pharmacokinetics of ASP3652
A Study to Assess the Pharmacokinetics, Metabolism and Excretion Routes of ASP3652 in Man, After Administration of 14C Radio Labeled ASP3652
This study measures how much of the trial drug enters the body and how long it takes for the body to remove it via the feces and urine.
- Trial name
- NCT02046798
- Testing
- ASP3652
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
Pharmacokinetics, Pharmacodynamics
A Study to Assess the Effect of Race on How a Single Dose of ASP3652 is Taken up, Metabolized and Distributed Through the Bodies of Young, Healthy Male and Female Subjects, and Its Safety and Tolerability
This study investigates how ASP3652 is taken up, broken down, and distributed through the body and excreted in individuals of different races.
- Conditions
- Pharmacokinetics, Pharmacodynamics, Healthy Subjects, Effect of Race
- Trial name
- NCT01958047
- Testing
- ASP3652
- Where
- United Kingdom
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
Drug-Drug Interaction (DDI), Healthy Subjects
A Study to Assess the Effect of Multiple Doses of Gemfribozil on a Single Dose of ASP3652, and to Assess the Effects of Multiple Doses of ASP3652 on a Single Dose of Repaglinide in the Body of Healthy Subjects
ASP3652 is being investigated as a novel treatment for chronic pelvic pain. This is a two-part study to investigate the drug-drug potential of ASP3652.
- Trial name
- NCT01797198
- Testing
- ASP3652, Gemfibrozil, Repaglinide
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.